

WORKING DOCUMENT SANTE/2017/10186

Guidelines for the Union co-funded programmes of eradication, control and surveillance of animal diseases and zoonoses for the years 2018-2020



DOCUMENTO DE TRABAJO SANTE / 2017/10186

"Directrices para los programas cofinanciados por la Unión de erradicación, control y vigilancia de enfermedades animales y zoonosis para los años 2018-2020"

Dirección General de Seguridad y Salud Alimentaria de la UE.

Grupo 1: enfermedades con un gran impacto en la salud animal y en el comercio

Group 1: diseases with major impact on animal health, and on trade

African swine fever			
	Baseline 2015	Expected results 2018	Expected results 2020
Non-affected Member States	23	23	23

Classical swine fever			
	Baseline 2015	Expected results 2018	Expected results 2020
Outbreaks	0	0	0

Avian influenza⁴			
	Baseline 2015	Expected results 2018	Expected results 2020
Percentage of secondary outbreaks in domestic birds reported to the total number of outbreaks	85%	Less than 85%	Less than 85%

Grupo 2: enfermedades con impacto en la salud humana y / o animal y cerca de erradicación, cuando sea factible

Group 2: diseases with impact on human health and/or animal health and close to eradication, when feasible

Rabies			
	Baseline 2015	Expected results 2018	Expected results 2020
No of cases ⁵	128	15	0

Bovine brucellosis			
	Baseline 2015 ⁶	Expected results 2018	Expected results 2020
Member States with an approved co-funded programme	5 Member States (ES, IT, PT, HR, UK)	3 Member States (UK and HR already free)	2 Member States (ES already free)

⁴ The achievement of this expected result will depend on the evolution of the disease situation which is difficult to predict due to multifactorial aspects, including mainly the wild birds migration.

⁵ Excluding cases in bats and imported cases

⁶ Baseline 2015 calculated on the entire Member State

Herd incidence (in %)			
	Baseline 2015	Minimum % of reduction compared to 2015	Minimum % of reduction compared to 2018
EL	0,4	20%	20%
ES	0,08	50%	100% = Free
IT	0,32	50%	100% = Free
PT	0,61	30%	30%

Transmissible spongiform encephalopathies			
	Baseline 2015	Expected results 2018	Expected results 2020
Classical bovine spongiform encephalopathy	2 cases 20 Member States with a negligible BSE risk	Less than 5 cases 24 Member States with a negligible BSE risk	Less than 5 cases 25 Member States with a negligible BSE risk
Classical scrapie	9 Member States with no classical scrapie cases over last 7 years	10 Member States with no classical scrapie cases over last 7 years	12 Member States with no classical scrapie cases over last 7 years

Zoonotic <i>Salmonella</i> in certain poultry populations			
	Baseline 2015	Expected results 2018	Expected results 2020
Member States with all poultry populations	23	24	26

Grupo 3: enfermedades que han sido introducidas o probablemente en riesgo de ser introducidas en el Territorio de la Unión de terceros países

Group 3: diseases which have been introduced or likely at risk to be introduced into the Union territory from third countries

Lumpy skin disease			
	Baseline 2015	Expected results 2018	Expected results 2020
Number of outbreaks	0	0	0

Peste des petits ruminants			
	Baseline 2015	Expected results 2018	Expected results 2020
Number of outbreaks	0	0	0

Sheep and goat pox			
	Baseline 2015	Expected results 2018	Expected results 2020
Number of outbreaks	0	0	0

Grupo 4: enfermedades con impacto limitado en la salud animal y / o la salud humana

Group 4: diseases with limited impact on animal health and/or human health

Bovine tuberculosis			
	Baseline 2015 ⁹	Expected results 2018	Expected results 2020
Member States with an approved co-funded programme	6 Member States (AT, ES, IE, IT, PT, UK)	5 Member States (AT officially free)	5 Member States (AT officially free)
Herd prevalence (in %)			
	Baseline 2015	Minimum % of reduction compared to 2015	Minimum % of reduction compared to 2018
ES	2,81	20%	20%
IE	3,53	20%	20%
IT	0,48	20%	20%
PT	0,33	20%	20%
UK	13,72	20%	20%
Herd incidence (in %)			
	Baseline 2015	Minimum % of reduction compared to 2015	Minimum % of reduction compared to 2018
ES	2,02	20%	20%
IE	3,37	20%	20%

⁹ Baseline 2015 calculated on the entire Member State

- Possibility of new measures eligible for EU co-financing; such measures should focus on prevention of transmission and on enhancing biosecurity,
- Increase of the EU financial contribution for these MSs (acceptance of more measures (e.g. more official sampling visits, more laboratory tests),
- Over the years the incidence should constantly decrease until it reaches the EU target; on the other hand the Commission could decide to stop this specific regime after two consecutive years without decrease of the incidence,
- The specific regime would stop one year after the EU target is reached.

7.7. Distribution of the funds per disease

All the diseases listed in the four groups are expected to be co-funded. Nevertheless, the budget available will be allocated in priority to groups 1, 2 and 3.

Within the budget available, the Commission should ensure an adequate balance of funds allocated within each disease.

7.7. Distribución de los fondos por enfermedad

Se espera que todas las enfermedades enumeradas en los cuatro grupos sean cofinanciadas. Sin embargo, el presupuesto disponible se asignará con prioridad a los grupos 1, 2 y 3. Dentro del presupuesto disponible, la Comisión debería garantizar un equilibrio adecuado de fondos asignado dentro de cada enfermedad